Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

(2015) L Kalmanti et al.   LEUKEMIA

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

(2014) T. P. Hughes et al.   BLOOD

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY